By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche said today that it has partnered with Cellular Dyanmics and Acea Biosciences on technologies for the early and accurate prediction of cardiotoxic side effects in the drug discovery process.

The alliance will combine Cellular Dynamics' induced pluripotent stem cell-derived heart cells, called iCell Cardiomyocytes, with Roche's xCelligence RTCA System, a label-free cell analysis system which was co-developed by Acea.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.